Background: The sequence and temporal relationship between Raynaud’s phenomenon (RP) and the first non-Raynaud’s sign/symptom (NRP) in systemic sclerosis (SSc) have been partially investigated. Objectives: To evaluate whether the mode and ages of clinical onset are associated with disease endotype and survival in SSc. Design: We included SSc patients from the Systemic sclerosis Progression INvestiGation registry of the Italian Society of Rheumatology (SPRING-SIR) registry in a cohort study, with post hoc cross-sectional and longitudinal analysis. Methods: Patients were grouped based on age-RP and age-NRP quartiles. Additionally, categories were defined based on mode of onset: RP group—RP onset at least 1 year before NRP; Simultaneous group—RP onset within the same year of NRP; NRP group—RP onset after at least 1 year after NRP. Comparisons were made using Chi-square and ANOVA tests. Logistic, linear, and multinomial regression models were applied to assess associations, while Kaplan–Meier curves and Cox regression were used to assess mortality. Results: A total of 1748 patients were eligible: 682 (39.0%) in the RP group, 1026 (58.8%) in the simultaneous group, and 39 (2.2%) in the NRP group. A higher prevalence of anti-centromere antibodies was found In the RP group, while the simultaneous group had more diffuse cutaneous SSc (dcSSc), anti-topoisomerase-I antibodies, and higher Rodnan’s skin score (mRSS). The NRP group presented higher prevalence of pulmonary arterial hypertension. On logistic regression, the simultaneous group was associated with a higher prevalence of dcSSc compared to the RP group (odds ratio, 1.491, 95% confidence interval (CI): 1.032–2.154). Younger age at RP onset was associated with lower systolic pulmonary artery pressure and mRSS. In 943 patients with available follow-up (median 24 months), the simultaneous group had higher mortality compared to the RP group (hazard ratio, 1.975, 95% CI: 1.002–3.893). Conclusion: The timing of RP and NRP onset may help define SSc endotype and survival. Patients with simultaneous RP-NRP onset have more severe disease features and higher mortality risk, emphasizing the relevance of onset timing in disease stratification.

Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) / S. Peretti, C. Bruni, F. Bonomi, R. De Angelis, G. Bajocchi, D. Giuggioli, M. Orlandi, G. Zanframundo, R. Foti, E. Visalli, G. Cuomo, A. Ariani, E. Rosato, G. Lepri, F. Girelli, V. Riccieri, E. Zanatta, S.L. Bosello, I. Cavazzana, F. Ingegnoli, M. De Santis, F. Cacciapaglia, G. Murdaca, G. Abignano, G. Pettiti, A. Della Rossa, M. Caminiti, A. Iuliano, G. Ciano, L. Beretta, G. Bagnato, E. Lubrano, I. De Andres, L. Idolazzi, M. Saracco, C. Agnes, C. Campochiaro, G. De Luca, E. Cipolletta, M. Fornaro, F. Lumetti, A. Spinella, L. Magnani, V. Codullo, C. Iandoli, A. Gigante, G. Pellegrino, E. Pigatto, M.G. Lazzaroni, E. De Lorenzis, G.A. Mennillo, M.D. Battista, G. Pagano Mariano, F. Furini, L. Vultaggio, S. Parisi, C.L. Peroni, G. Bianchi, E. Fusaro, G.D. Sebastiani, M. Govoni, S. D'Angelo, F. Cozzi, F. Franceschini, S. Guiducci, L. Dagna, A. Doria, C. Salvarani, M.A. D'Agostino, F. Iannone, M. Matucci-Cerinic, C. Ferri, S.B. Randone. - In: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. - ISSN 1759-720X. - 18:(2026 Feb 05), pp. 1759720X251410243.1-1759720X251410243.19. [10.1177/1759720x251410243]

Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR)

F. Ingegnoli;G. Pellegrino;
2026

Abstract

Background: The sequence and temporal relationship between Raynaud’s phenomenon (RP) and the first non-Raynaud’s sign/symptom (NRP) in systemic sclerosis (SSc) have been partially investigated. Objectives: To evaluate whether the mode and ages of clinical onset are associated with disease endotype and survival in SSc. Design: We included SSc patients from the Systemic sclerosis Progression INvestiGation registry of the Italian Society of Rheumatology (SPRING-SIR) registry in a cohort study, with post hoc cross-sectional and longitudinal analysis. Methods: Patients were grouped based on age-RP and age-NRP quartiles. Additionally, categories were defined based on mode of onset: RP group—RP onset at least 1 year before NRP; Simultaneous group—RP onset within the same year of NRP; NRP group—RP onset after at least 1 year after NRP. Comparisons were made using Chi-square and ANOVA tests. Logistic, linear, and multinomial regression models were applied to assess associations, while Kaplan–Meier curves and Cox regression were used to assess mortality. Results: A total of 1748 patients were eligible: 682 (39.0%) in the RP group, 1026 (58.8%) in the simultaneous group, and 39 (2.2%) in the NRP group. A higher prevalence of anti-centromere antibodies was found In the RP group, while the simultaneous group had more diffuse cutaneous SSc (dcSSc), anti-topoisomerase-I antibodies, and higher Rodnan’s skin score (mRSS). The NRP group presented higher prevalence of pulmonary arterial hypertension. On logistic regression, the simultaneous group was associated with a higher prevalence of dcSSc compared to the RP group (odds ratio, 1.491, 95% confidence interval (CI): 1.032–2.154). Younger age at RP onset was associated with lower systolic pulmonary artery pressure and mRSS. In 943 patients with available follow-up (median 24 months), the simultaneous group had higher mortality compared to the RP group (hazard ratio, 1.975, 95% CI: 1.002–3.893). Conclusion: The timing of RP and NRP onset may help define SSc endotype and survival. Patients with simultaneous RP-NRP onset have more severe disease features and higher mortality risk, emphasizing the relevance of onset timing in disease stratification.
Raynaud’s phenomenon; disease onset; non-Raynaud’s symptoms; risk assessment; systemic sclerosis
Settore MEDS-09/C - Reumatologia
5-feb-2026
Article (author)
File in questo prodotto:
File Dimensione Formato  
Age and onset timing of Raynaud’s phenomenon.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Licenza: Creative commons
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1239856
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
  • OpenAlex ND
social impact